GTHX - G1セラピュ―ティクス (G1 Therapeutics Inc.) G1セラピュ―ティクス

 GTHXのチャート


 GTHXの企業情報

symbol GTHx
会社名 G1 Therapeutics Inc (G1セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 G1セラピューティクス(G1 Therapeutics Inc.)は臨床段階のバイオ医薬品会社である。同社はがん治療用小分子療法の開発に従事する。同社の2つの臨床段階の候補はキナーゼ標的CDK4 / 6の選択的阻害剤であるトリラシクリブ(G1T28)およびG1T38である。トリラシクリブおよびG1T38は現在の治療法の抗腫瘍活性を増強するように設計される。同社はまた、乳癌の治療用経口選択的エストロゲン受容体分解酵素(SERD)であるG1T48を開発中である。3つの第II相臨床試験において、同社はトリラシクリブを評価する。G1T38はエストロゲン受容体陽性HER2陰性乳癌患者のフェーズI b / II試験において、Faslodexと組み合わせて評価される。   G1セラピュ―ティクスは米国のバイオ医薬品企業。臨床ステ―ジで、がん治療の新薬や治療法の発見・開発に従事する。細胞肺がんの治療用サイクリン依存性キナ―ゼ(CDK)4/6阻害薬と、乳がん治療用の経口タイプCDK4/6阻害薬やエストロゲン受容体ディグレ―ダ―などの新薬を開発する。本社所在地はノ―スカロライナ州リサ―チ・トライアングル・パ―ク。   
本社所在地 79 T.W. Alexander Drive 4501 Research Commons Suite 100 Research Triangle Park NC 27709 USA
代表者氏名 Seth A. Rudnick Seth A. Rudnick
代表者役職名 Independent Chairman of the Board
電話番号 +1 919-213-9835
設立年月日 39569
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数
url www.g1therapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/gthx
adr_tso
EBITDA EBITDA(百万ドル) -75.46400
終値(lastsale) 43.93
時価総額(marketcap) 1467461222.55
時価総額 時価総額(百万ドル) 1688.8
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 1500.573
当期純利益 当期純利益(百万ドル) -73.86000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 G1 Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 28% to $41.3M. Higher net loss reflects Research_Development - Balancing value increase of 40% to $33.3M (expense) General and Administrative - Balancing increase of 100% to $5.4M (expense) Stock-based Compensation in R&D increase from $1M to $2.4M (expense).

 GTHXのテクニカル分析


 GTHXのニュース

   H.C. Wainwright Stick to Their Buy Rating for G1 Therapeutics Inc By Investing.com  2021/04/12 10:15:59 Investing.com
H.C. Wainwright Stick to Their Buy Rating for G1 Therapeutics Inc
   Needham Stick to Their Buy Rating for G1 Therapeutics Inc By Investing.com  2021/04/09 20:15:01 Investing.com
Needham Stick to Their Buy Rating for G1 Therapeutics Inc
   Thinking about buying stock in G1 Therapeutics, Strongbridge Biopharma, Soligenix, Pieris Pharmaceuticals, or Diffusion Pharmaceuticals?  2021/02/16 13:31:00 PR Newswire
NEW YORK, Feb. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GTHX, SBBP, SNGX, PIRS, and DFFN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   G1 Therapeutics Wins FDA Approval For COSELA Drug; Shares Pop 20%  2021/02/14 09:07:26 Smarter Analyst
G1 Therapeutics announced that the US Food and Drug Administration (FDA) has approved its COSELA drug as a first-of-its-kind treatment for patients with … The post G1 Therapeutics Wins FDA Approval For COSELA Drug; Shares Pop 20% appeared first on Smarter Analyst .
   The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed  2021/02/12 13:10:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 12) 4D Molecular Therapeutics Inc (NASDAQ: FDMT ) Adagene Inc (NASDAQ: ADAG ) (went public Tuesday) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) AnaptysBio Inc (NASDAQ: ANAB ) (received a double upgrade from JPMorgan) AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Bausch Health Companies Inc (NYSE: BHC ) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) DermTech Inc (NASDAQ: DMTK ) ( announced award of contract for coverage of its skin cancer gene expression test) ESSA Pharma Inc (NASDAQ: EPIX ) (reacted to first-quarter results) Evogene Ltd (NASDAQ: EVGN ) FibroGen Inc (NASDAQ: FGEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) (moved on M&A speculation) Guardant Health Inc (NASDAQ: GH ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunome Inc (NASDAQ: IMNM ) Infinity Pharmaceuticals Inc.
   Thinking about buying stock in G1 Therapeutics, Strongbridge Biopharma, Soligenix, Pieris Pharmaceuticals, or Diffusion Pharmaceuticals?  2021/02/16 13:31:00 PR Newswire
NEW YORK, Feb. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GTHX, SBBP, SNGX, PIRS, and DFFN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   G1 Therapeutics Wins FDA Approval For COSELA Drug; Shares Pop 20%  2021/02/14 09:07:26 Smarter Analyst
G1 Therapeutics announced that the US Food and Drug Administration (FDA) has approved its COSELA drug as a first-of-its-kind treatment for patients with … The post G1 Therapeutics Wins FDA Approval For COSELA Drug; Shares Pop 20% appeared first on Smarter Analyst .
   The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed  2021/02/12 13:10:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 12) 4D Molecular Therapeutics Inc (NASDAQ: FDMT ) Adagene Inc (NASDAQ: ADAG ) (went public Tuesday) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) AnaptysBio Inc (NASDAQ: ANAB ) (received a double upgrade from JPMorgan) AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Bausch Health Companies Inc (NYSE: BHC ) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) DermTech Inc (NASDAQ: DMTK ) ( announced award of contract for coverage of its skin cancer gene expression test) ESSA Pharma Inc (NASDAQ: EPIX ) (reacted to first-quarter results) Evogene Ltd (NASDAQ: EVGN ) FibroGen Inc (NASDAQ: FGEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) (moved on M&A speculation) Guardant Health Inc (NASDAQ: GH ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunome Inc (NASDAQ: IMNM ) Infinity Pharmaceuticals Inc.
   The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts  2021/02/11 12:26:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X Genomics Inc (NASDAQ: TXG ) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Abbott Laboratories (NYSE: ABT ) Acasti Pharma Inc (NASDAQ: ACST ) (reacted to its quarterly results) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Alkermes Plc (NASDAQ: ALKS ) Allakos Inc (NASDAQ: ALLK ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Apyx Medical Corp (NASDAQ: APYX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Artelo Biosciences Inc (NASDAQ: ARTL ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) AtriCure Inc. (NASDAQ: ATRC ) Avanos Medical Inc (NYSE: AVNS ) Beigene Ltd (NASDAQ: BGNE ) Bio-Path Holdings Inc (NASDAQ: BPTH ) (announced receipt of third patent related to manufacture of platform technology) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cancer Genetics Inc (NASDAQ: CGIX ) (reacted to an update to merger terms with StemoniX) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Clearside Biomedical Inc (NASDAQ: CLSD ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) Edap Tms SA (NASDAQ: EDAP ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Gamida Cell Ltd (NASDAQ: GMDA ) ( reacted to a positive late-stags readout) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Ideaya Biosciences Inc (NASDAQ: IDYA ) Illumina, Inc.
   Glancy Prongay & Murray LLP Announces Investigation of G1 Therapeutics, Inc.  2021/01/26 20:22:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of G1 Therapeutics, Inc. (Nasdaq: GTHX) concerning the Company and its directors’ and officers’ possible violations of state laws. If you purchased G1 Therapeutics stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 530, New York, NY 1

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 G1セラピュ―ティクス GTHX G1 Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)